NCT05856760 Phase 2 Completed
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Study sponsor: Travere Therapeutics, Inc. · TVTX
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2024-10-14 Actual
Enrollment · participants 48 Actual
Source updated 2025-11-20 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2025-10-23 · 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Change in urine albumin-creatinine ratio (UA/C) at Week 24
+ After Measure: Change in Urine Albumin -creatinine Ratio (UA/C) at Week 24
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial